The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Identifying tumor-reactive T-cell clones to guide personalized immunotherapy in multiple myeloma
David Avigan, MD, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, discusses potential clinical applications of identifying tumor-reactive T-cell clones in multiple myeloma at the single-cell level. He highlights the potential to identify highly immunogenic shared neoepitopes to guide personalized vaccines and engineered T-cell approaches, as well as strategies to sustain immune responses following CAR-T or bispecific therapy and reduce the risk of relapse. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
